RDHL
Redhill Biopharma Ltd
NASDAQ: RDHL · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.04
+0.00% today
Updated 2026-04-29
Market cap
$5.27M
P/E ratio
0.00
P/S ratio
0.55x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$1 – $3
Volume
0.0M
Redhill Biopharma Ltd (RDHL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-97.50%
Operating margin
-107.30%
ROE
-1,709.00%
ROA
-25.30%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2010 | — | $-2.54M | — | — | — |
| 2011 | $23000.00 | $-15.50M | 100.00% | -34,230.43% | -67,404.35% |
| 2012 | $16000.00 | $-10.33M | 100.00% | -56,500.00% | -64,537.50% |
| 2013 | $12000.00 | $-10.63M | 100.00% | -89,766.67% | -88,566.67% |
| 2014 | $7.01M | $-10.71M | 85.03% | -151.80% | -152.71% |
| 2015 | $3000.00 | $-21.09M | -733,300.00% | -733,400.00% | -703,000.00% |
| 2016 | $101000.00 | $-29.37M | -30,140.59% | -30,240.59% | -29,079.21% |
| 2017 | $4.01M | $-45.54M | 46.94% | -1,297.03% | -1,136.61% |
| 2018 | $8.36M | $-38.82M | 66.06% | -470.47% | -464.35% |
| 2019 | $6.29M | $-42.30M | 64.09% | -686.71% | -672.45% |
| 2020 | $64.36M | $-76.17M | 42.68% | -98.95% | -118.36% |
| 2021 | $85.76M | $-97.74M | 42.39% | -94.61% | -113.98% |
| 2022 | $61.80M | $-71.67M | 46.06% | -69.33% | -115.97% |
| 2023 | $6.53M | $23.92M | 47.03% | 193.45% | 366.25% |
| 2024 | $8.04M | $-8.27M | 60.31% | -181.69% | -102.80% |